Inhibitor Therapeutics (INTI) Shares Outstanding (2012 - 2026)

Inhibitor Therapeutics (INTI) has 15 years of Shares Outstanding (Entity) data on file, last reported at $172.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) changed 0.15% year-over-year to $172.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.6 million (changed 0.15% YoY) and the FY2025 annual result came in at $172.6 million, changed 0.15% from the prior year.
• Shares Outstanding (Entity) steadied at $172.6 million in Q1 2026, from $172.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $376.9 million in Q1 2022 to a low of $171.8 million in Q1 2023.
• A 5-year average of $219.8 million and a median of $172.3 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) plunged 54.41% — and 2024, when it gained 0.31%.
• Tracing INTI's Shares Outstanding (Entity) over 5 years: stood at $366.2 million in 2022, then plunged by 53.02% to $172.0 million in 2023, then climbed by 0.17% to $172.3 million in 2024, then gained by 0.15% to $172.6 million in 2025, then changed by 0.0% to $172.6 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $172.6 million (Q1 2026), $172.6 million (Q4 2025), and $172.6 million (Q3 2025), per Business Quant data.